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Currently, presymtomatic hematopoietic stem and pro-
genitor cell transplantation (HSPCT) is the only therapeu-
tic modality that alleviates Krabbe’s disease (KD)-induced
central nervous system damage. However, all HSPCT-
treated patients exhibit severe deterioration in peripheral
nervous system function characterized by major motor
and expressive language pathologies. We hypothesize
that a combination of several mechanisms contribute to
this phenomenon, including 1) nonoptimal conditioning
protocols with consequent inefficient engraftment and
biodistribution of donor-derived cells and 2) insufficient
uptake of donor cell-secreted galactocerebrosidease
(GALC) secondary to a naturally low expression level of
the cation-independent mannose 6-phosphate-receptor
(CI-MPR). We have characterized the effects of a busulfan
(Bu) based conditioning regimen on the efficacy of
HSPCT in prolonging twi mouse average life span. There
was no correlation between the efficiency of bone mar-
row engraftment of donor cells and twi mouse average
life span. HSPCT prolonged the average life span of twi
mice, which directly correlated with the aggressiveness
of the Bu-mediated conditioning protocols. HSPC trans-
duced with lentiviral vectors carrying the GALC cDNA
under control of cell-specific promoters were efficiently
engrafted in twi mouse bone marrow. To facilitate
HSPCT-mediated correction of GALC deficiency in target
cells expressing low levels of CI-MPR, a novel GALC
SIGNIFICANCE
Although presymtomatic hematopoietic stem and progenitor cell
transplantation (HSPCT) is the standard therapeutic modality for
Krabbe’s disease, it fails to provide a curative solution. Newly devel-
oped lentiviral vectors carrying myeloid- and erythroid-specific pro-
moters improve the therapeutic potential of HSPCT by facilitating
GALC delivery to host HSPC without compromising their ability to
engraft the host bone marrow. Low levels of CI-MPR (also known
as IGF2R) may limit the efficacy of HSPCT for curing KD. A novel
GALC-AErdb fusion whose uptake by host cells is mediated by an
IGF2R-independent pathway may resolve this limitation. It appears
that an aggressive busulfan conditioning protocol significantly extends
the life span of twi mice.
Contract grant sponsor: Legacy of Angels Foundation (to T.K., P.H.,
E.R.B.); Contract grant sponsor: National Institutes of Health; Contract
grant numbers: RO1DK058702 (to T.K., P.H.); R01HL128119-01 (to
T.K., P.H.); RO1NS084861 (to M.S.S., Y.L.); R01NS065808 (to
E.R.B.); R21NS087474 (to E.R.B.)
*Correspondence to: T. Kafri, Gene Therapy Center and Department of
Microbiology and Immunology, University of North Carolina at Chapel
Hill, 5019 Thurston Bowles, CB 7352, Chapel Hill, NC 27599-7352.
E-mail: kafri@med.unc.edu
Received 18 April 2016; Revised 11 June 2016; Accepted 4 July 2016
Published online 17 September 2016 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/jnr.23847
VC 2016 The Authors. Journal of Neuroscience Research Published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and dis-
tribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Journal of Neuroscience Research 94:1152–1168 (2016)
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Carolina Digital Repository
fusion protein including the ApoE1 receptor was devel-
oped. Efficient cellular uptake of the novel fusion protein
was mediated by a mannose-6-phosphate-independent
mechanism. The novel findings described here elucidate
some of the cellular mechanisms that impede the cure of
KD patients by HSPCT and concomitantly open new
directions to enhance the therapeutic efficacy of HSPCT
protocols for KD. VC 2016 The Authors. Journal of Neurosci-
ence Research Published by Wiley Periodicals, Inc.
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Neonatal bone marrow transplantation (BMT) pro-
vides significant (although incomplete) protection for ear-
ly infantile Krabbe’s dieaese (KD) patients’ central
nervous system (CNS), preserves their cognitive function,
and appears to lengthen their survival (mean of 23–25
months without treatment) up to the second decade of
life (Escolar et al., 2005; Duffner et al., 2009, 2011; Was-
serstein et al., 2016). However, BMT cannot effectively
alleviate the motor and sensory deficiencies caused by
peripheral demyelination. This therapeutic approach is
premised on the ability of the donor’s hematopoietic stem
and progenitor cells (HSPC) and their progenies to colo-
nize the host CNS and to secrete functional GALC,
which upon mannose-6-phosphate (M6P)-mediated
uptake compensates for the lack of host GALC function.
Failure to efficiently complete any of these processes
potentially contributes to the mechanism that renders KD
incurable by HPCT. Host conditioning is aimed at gener-
ating space for donor HSPC in host target niches and is
considered critical for efficient engraftment. Although not
applicable for KD patients, total body irradiation (TBI) is
the conditioning method employed in most HSPCT-
based preclinical studies of KD (Lin et al., 2007; Gentner
et al., 2010). Notwithstanding the major impact of the
conditioning protocol on the clinical outcome of HSPCT
in lysosomal storage disorder (LSD) patients, the effects of
the aggressiveness of the conditioning protocol on the
pathologic course of KD have not been evaluated in a
preclinical model. The ability of GALC-deficient host
cells to take up extracellular GALC efficiently is the pre-
mise of the HSPCT-based therapy for KD. Both the
cation-dependent and the cation-independent M6P
receptors (CD-MPR and CI-MPR) mediate intracellular
trafficking of lysosomal enzymes. However, only the CI-
MPR (also known as IGF2R) facilitates uptake of extra-
cellular proteins via the M6P receptor (M6PR) pathway
(Munier-Lehmann et al., 1996; Dahms et al., 2008; Stein
et al., 2010). Several research groups have demonstrated
that expression of IGF2R in rodent and human CNS is
cell type specific (Nissley et al., 1993; Gonzalez-Parra
et al., 2001; Hawkes and Kar, 2003, 2004; Jofre et al.,
2009). Thus, naturally low levels of IGF2R expression in
various cell populations could potentially reduce the
therapeutic efficacy of HSPCT for KD patients. The abil-
ity to mediate cellular uptake of GALC via an M6P-
independent pathway should address this potential weak-
ness. Recent publications described the development of a
fusion protein comprising the ApoE1-receptor binding
domain (AErbd) and the lysosomal protein a-L-
iduronidase (IDUA; Wang et al., 2013; Dai et al., 2014).
This facilitated cellular uptake and transcytosis of the nov-
el fusion protein to the CNS via the low-density lipopro-
tein (LDL) receptor-related protein 1 (LRP-1) pathway,
independently of the M6P pathway. Premised on this
technology, a novel GALC-AErbd fusion protein can
potentially be used to treat cell populations that naturally
do not express sufficient IGF2R.
To date, preclinical trials employing viral vectors for
GALC delivery failed to significantly alter the pathologic
course of KD in the twi mouse model (Lin et al., 2005,
2007; Gentner et al., 2010; Ungari et al., 2015). Notwith-
standing the ongoing growth in the pool of potential
bone marrow (BM) donors, it is still possible that the lack
of a matched allogeneic donor will render KD patients
unsuitable for HSPCT. The ability of lentiviral vectors to
efficiently transduce and maintain long-term transgene
expression in patients’ HSPC and their differentiated
progenies has been employed in human clinical trials to
establish therapeutic autologous HSPC-based gene
replacement protocols for adrenoleukodystrophy (Cartier
et al., 2009), metachromatic leukodystrophy (Biffi et al.,
2013) and Wiscott-Aldrich syndrome (Aiuti et al., 2013)
patients for whom a matched donor could not be identi-
fied. However, cytotoxicity associated with lentiviral
vector-mediated GALC expression in HSPC poses a
potential hurdle in employing the aforementioned thera-
peutic approach for KD patients (Gentner et al., 2010;
Visigalli et al., 2010). By incorporating a tandem of target
sequences of the HSPC-specific micro-RNA mir126
investigators (Gentner et al., 2010; Ungari et al., 2015)
minimized GALC expression in HSPC and efficiently
engrafted human and mouse HSPC that had been trans-
duced with lentiviral vectors from which the human PGK
promoter regulated expression of functional GALC
mRNA. We assert that overexpression of target sequence
of host miRNAs may alter the natural miRNA system
(Ebert and Sharp, 2010). On the other hand, lentiviral
vectors that express functional GALC under the control
of cell-specific promoters would further enhance expres-
sion of GALC in the relevant HSPC progenies (e.g.,
microglia), with minimal GALC expression in HSPC.
This strategy should facilitate therapeutic autologous
HSPCT in KD patients without posing risk/benefit con-




THP-1 cells were cultured in RPMI1640 (Hyclone,
Logan, UT) with 10% FBS (Atlantic Biologicals, Miami, FL),
2 mM glutamine (Corning Cellgro, Manassas, VA), 100 U/ml
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penicillin, 100 mg/ml streptomycin, and 250 ng/ml amphoteri-
cin B (Corning Cellgro). Murine erythroleukemia (MEL) and
293T cells were maintained in DMEM High-Glucose
(Hyclone) supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, and 250 ng/ml amphotericin B. Dur-
ing the differentiation, MEL cells were induced by 5 mM hex-
amethylene bisacetamide (HMBA) and supplemented with 20%
FBS. Lineage-negative cells purified using a mouse lineage cell
depletion kit (Miltenyi Biotechnology, San Diego, CA) were
cultured in Stem Span SFEM medium (Stemcell, Vancouver,
British Columbia, Canada) with 100 ng/ml mouse stem cell
factor (SCF), 100 ng/ml Flt3 ligand, 100 ng/ml IL3, and
100 ng/ml TPO (Sigma, St. Louis, MO).
Plasmids
The lentiviral vector packaging cassette DNRF and the
VSV-G envelope plasmid were described previously (Kafri
et al., 1999). Promoter sequences and codon-optimized GALC
cDNA’s were synthesized by GeneArt (Thermo Fisher). The
relevant DNA fragments were cloned into lentiviral vectors
(pTK134 or pTK208). Vector structures were verified by
restriction enzyme analysis and/or sequencing.
Luciferase Assay
Luciferase expression was measured by the Luciferase
Assay system from Promega (Madison, WI). Briefly, virus-
transduced cells were lysed with lysis buffer and analyzed on
1420 Multilabel Counter Victor 3 (PerkinElmer, Waltham,
MA). Activities were further normalized with protein concen-
tration and viral copy number (VCN) per cell. Protein concen-
tration was determined by the Bradford method.
VCN Quantification
VCN was quantified by multiplex PCR (Suwanmanee
et al., 2013) on an ABI7300 real-time PCR system. NotI794
primer/prober set (left primer 50-taagaccaccgcacagca-30, right
primer 50-cacttctccaattgtccctca-30; No. 25; Roche Universal
Probe Library [UPL]) was used for vectors detection, and paired
with two different reference genes, mouse GAPDH primer/
probe set or human GUSB primer/probe set (Roche, Indianap-
olis, IN). DNA samples were treated with dpn I to minimize
plasmid contamination before PCR analysis.
293T Uptake and Galc Activity Assay
Cells were incubated with medium containing different
GALC variants at 37 8C for 3 hr. After three PBS washes, cells
were lysed with RIPA buffer on ice for 30 min. Cell lysates
were cleared by centrifugation at 12,000 rpm for 5 min at 4 8C
and assayed for GALC activity. For M6P inhibition, 293T cells
were pretreated with or without 1 mM M6P for 30 min, fol-
lowed by incubation of conditioned media with different
GALC proteins.
GALC activity assay was performed as described previ-
ously (Martino et al., 2009). Briefly, cells were lysed in RIPA
buffer supplemented with protease inhibitors (Sigma). Proteins
(10 ml, 5–10mg) were incubated with the artificial fluorogenic
substrate 4-methylumbelliferone-galactopyranoside (1.5 mmol/
liter) resuspended in 100 ml 0.1/0.2 mol/liter citrate/phosphate
buffer, pH 4.0, in the presence of 11 mmol/liter AgNO3 at
37 8C for 30 min, followed by treatment with 0.2 M sodium
carbonate buffer. Fluorescence of liberated 4-MU was mea-
sured on the 1420 Multilabel Counter Victor 3. Free 4-
methylumbelliferone (4-MU; Sigma) was used as a standard to
calibrate b-galactosidase activity. Results were normalized with
protein concentration.
Primary Fibroblast Culture and GALC Activity Assay
Human fibroblasts derived from two patients and two unaf-
fected healthy donors (GM06806, GM04913, GM00041,
GM08333; Coriell Institute) were seeded at a density of 10,000
cells/cm2 in growth medium (DMEM, 15% FBS, 2 mM L-
glutamine, nonessential amino acids, penicillin/streptomycin 100
U/ml; Thermo Scientific, Pleasanton, CA). After 2 days, the
medium was replaced and changed daily with growth medium
supplemented with supernatant derived from cells overexpressing
GALC or GALC-AErdb and from cells transfected with the sole
vector as a control. Sister cultures were also treated with 2.5 mM
M6P. This treatment was carried out in duplicate for 3 days, after
which the cells were washed twice with PBS, collected, pelleted,
and resuspended in distilled H2O for GALC activity analysis. Cell
suspensions were sonicated (three pulses, 3 sec each, 30% intensi-
ty) and used to perform the GALC activity assay, as described by
Wiederschain et al. (1992). Briefly, 10 ll lysate was added to 20ll
of a substrate solution containing 6-hexadecanoylamino-4-
methylumbelliferyl-b-D-galactoside (HMU-b-GAL), mixed,
and incubated for 17 hr at 37 8C. After incubation, the reaction
was terminated with a solution containing 0.2% SDS and Triton
X-100, pH 10.7, and the fluorescence measured (ex. 370 nm, em.
535 nm) by fluorometry. Results were normalized for protein
content.
Animals
Female BoyJ mice (B6.SJL-Ptprca Pepcb/BoyJ; RRI-
D:IMSR_JAX:002014) at age 6–8 weeks were purchased
from the Jackson Laboratory. Heterozygous twitcher (GALC1/
2) mice on a congenic C57BL/6 background (RRID:IMSR_-
JAX:000845) were kindly provided by Dr. Steven J. Gray in
Gene Therapy Center, University of North Carolina at Chapel
Hill (UNC). The mouse colony was maintained under the
supervision of T.K., and all procedures were approved by the
Institutional animal care and use committee of UNC (IACUC
13-195.0). Genotyping was carried out by PCR with clipped
toe DNA’s before postnatal day 8 (date of birth counted as day
0). Briefly, the toes were lyzed in 25 mM NaOH/0.2 mM
EDTA at 98 8C for 90 min, followed by neutralization with
same volume of 40 mM Tris (pH 5.5). PCR (98 8C 3 min, fol-
lowed by 40 repeated cycles of 98 8C 10 sec, 62 8C 15 sec,
72 8C 20 sec) was performed with toe DNA and primer pair
(left primer 50-CACACAACCCAGTTTACTCAACC-30,
right primer 50-GATGGCCCACTGTCTTCAGG-30; Preci-
sion Melt Supermix; Bio-Rad, Hercules, CA). Melting curve
of knockouts, wild type, and heterozygotes was determined by
using a Roche light Cycle480. (The method was developed by
Steven J. Gray in the Gene Therapy Center at UNC.) End-
point reaching animals were euthanized by CO2 asphyxiation
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in accordance with UNC IACUC protocol (13-195.0). End-
point criteria included: weight loss of more than 25% of body
weight, difficulties in drinking, respiratory distress and severe
hind leg paralysis.
Brain Immunohistochemistry of L-Cycloserine-Treated
twi Mice
Animals received 25 mg/kg L-cycloserine (Sigma
Aldrich) subcutaneously three times per week starting at postna-
tal day 6. At postnatal day 21 mice were sacrificed and perfused
with PBS. Brains were isolated, fixed for 24 hr in 10% neutral
buffered formalin, then transferred to 70% ethanol. Further
processes, including tissue embedding, sectioning, HE staining,
immunohistochemistry staining, imaging, and analysis, were
performed in the UNC Translational Pathology Laboratory.
CI-M6PR rabbit monoclonal Ab (1:100; Cell Signaling Tech-
nology, Danvers, MA) was used for immunostaining. Data
were analyzed using the eSlide Manager and Image Scope from
Leica Biosystems (Buffalo Grove, IL).
Bone Marrow Transplantation
Animals in experimental groups were conditioned with
busulfan (Bu; Sigma; injected intraperitoneally [i.p.] (25 mg/kg)
at postnatal day 8. On the next day, fresh donor bone marrow
(BM) cells from BoyJ mouse tibia, femur, and pelvis were iso-
lated, counted and resuspended in PBS. Each conditioned ani-
mal received approximately 5 3 107 total BM cells via i.p.
injection.
For transduced lineage-negative BM cells, total BoyJ
bone marrow were isolated on the same day of mice condition-
ing. Isolated Lin– cells were transduced with lentiviral vectors
(vTK1667 or vTK 1784) at m.o.i. 50 (based on 293T cells) in
culture medium with an additional 10 mg/ml rapamycin (Sigma)
for 14–16 hr. Transduced Lin– cells were washed with PBS
and mixed with fresh isolated total BM cells for transplantation.
Each Bu-conditioned mouse received 1 x 106 Lin– cells trans-
duced with vTK1667, 1 x 106 Lin– cells transduced with
vTK1784, and 1 x 107 fresh isolated total BM cells from BoyJ
mice.
Viral Vector Production, Concentration, and Titration
Lentiviral vector production transient three-plasmid
transfection into 293T cells, and viral concentration were
described by Kafri et al. (Kafri et al., 1999).The following plas-
mid amounts were used: 15 mg transfer cassette, 10 mg DNRF
packaging construct, and 5 mg of the VSV-G envelope plasmid
pMD.G. Viral vectors were concentrated by sucrose gradient
ultracentrifugation. The emergence of replication competent
retroviruses (RCRs) was ruled out by three independent safety
assays (GFP rescue assay, Tat transfer assay, and Gag transfer
assay) as described earlier. Titers of physical vector particles
were determined by p24gag ELISA using the National Institutes
of Health p24 Antigen Capture Assay kit, as previously docu-
mented (Kantor et al., 2009). Infectious unit titers were deter-
mined by measuring VCN following infection on 293T cell.
Flow Cytometry Analysis
To measure BM engraftment, mouse BM cells from
femur/tibia were flushed by PBS and labeled for flow cytome-
try analysis. After Fc receptor block (BD Biosciences, San Jose,
CA), bone marrow cells were stained at 4 8C for 15 min with
the following antibodies (BD Biosciences): V450 mouse-
lineage antibody cocktail, PE-Cy7 rat anti-mouse Sca1, APC
rat anti-mouse cKit, PE mouse anti-mouse CD45.1, and FITC
mouse anti-mouse CD45.2. After fixation with 2% PFA at 4 8C
for 15 min, samples were ready for flow analysis.
To quantify the hematopoietic-derived cells in the CNS,
mice were perfused with 25 ml cold PBS before brain dissec-
tion. CNS-infiltrated lymphocyte isolation was performed as
described by Reddy et al. (2011). Briefly, isolated brains were
treated with collagenase buffer at room temperature for 30 min
after homogenization and passed through a 70-lm cell strainer.
The hematopoietic-derived cells were separated on a Percoll
(Sigma; GE17-0891) gradient. Cells were then blocked with Fc
receptor and stained with the following fluorophore-
conjugated antibodies: PE mouse anti-mouse CD45.1 (BioLe-
gend), FITC mouse anti-mouse CD45.2 (BD Biosciences;
561874), and rat APC anti-mouse CD11b (BD Biosciences;
553312). Fixed brain samples were used for flow analysis. All
the BM and brain data were acquired using CyAn ADP (Beck-
man Coulter) and analyzed with Summit5.2.
Antibody Characterization
See Table I for a list of all antibodies used. The IGF2R
(CD222) antibody detected only the expected protein (280
kD) on Western blot of mouse brain and liver. The staining
pattern of mouse and human tissues (APT84G1 and APT84E1)
and their cellular distribution were identical to those described
in the human protein atlas (www.proteinatlas.org). The
CD45.1 antibody did not react with mouse cells expressing the
CD45.2 alloantigen (manufacturer’s data sheet). The CD45.2
antibody exclusively detected mouse cells expressing the
CD45.2 alloantigen (manufacturer’s data sheet). FACscan anal-
ysis of BM cells obtained from either C57B6 or Boy.J exhibited
specific staining with CD45.2- and CD45.1-directed anti-
bodies, respectively, without detectable cross-reactivity. Mac1,
Sca-1, cKit (CD117), and lineage antibody cocktails were rou-
tinely tested by FACscan analysis and demonstrated population-
specific staining (manufacturer’s data sheet).
Statistical Analysis
All statistical analysis was performed via Student’s t-test in
Microsoft Excel.
RESULTS
Novel lentiviral vectors carrying myeloid- and ery-
throid/megakaryocytic-specific promoters facilitate
efficient GALC delivery to and engraftment of
hematopoietic stem cells in the twitcher (twi)
mouse model of KD.
More than 2,000 therapeutic BMTs in human
patients suffering from rare genetic disorders (Boelens
et al., 2014) attest to BMT as the cornerstone of all
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therapeutic regimens for LSD. This reality renders KD
patients for whom an HSPC donor could not be identi-
fied practically untreatable. The ability of lentiviral vec-
tors to efficiently deliver functional cDNAs to patients’
HSPC and to maintain therapeutic levels of transgene
products in their progenitors opens a promising thera-
peutic avenue that can circumvent the need for a match-
ing donor. However, recent studies focusing on
lentiviral vector-mediated GALC delivery to HSPC
indicated that GALC overexpression is toxic to HSPC
and inhibits the engraftment in hematopoietic tissues
(Gentner et al., 2010; Visigalli et al., 2010). We hypoth-
esized that novel lentiviral vectors from which functional
GALC cDNA is expressed under control of either mye-
loid or erythroid/megakaryocytic promoters would min-
imize toxic GALC expression in HSPC and would
facilitate efficient engraftment of vector-transduced
HSPC in hematopoietic tissues. To test this hypothesis,
we developed a series of novel vectors from which the
GFP and the firefly luciferase reporter genes, as well a
codon-optimized (CO) human GALC cDNA, were
expressed under control of either a myeloid- or ery-
throid/megakaryocyte-specific promoters. The myeloid
promoter was synthesized based on the nucleotide
sequence of the 146gp91 promoter described earlier (He
et al., 2006; Barde et al., 2011). The erythroid/megakaryo-
cyte promoter IHK was developed and characterized earli-
er (Moreau-Gaudry et al., 2001). Lentiviral vectors
carrying these cDNAs under control of a CMV promoter
served as controls (Fig. 1A). Cell-specific gene expression
from the aforementioned vectors was characterized in rele-
vant cell lines. Specifically, THP-1 and hexamethylene
bisacetamide (HMBA)-induced mouse erythroleukemia
cells (MELs) served as myeloid and erythroid reporter cell
lines, respectively. Vector-transduced 293T cells served as
controls. As shown in Figure 1B–D and Table II, highly
cell-specific gene expression was exhibited for the 146gp91
and the IHK promoters in the relevant THP-1 and
HMBA-induced MEL cells, respectively. Furthermore,
GFP expression under control of the 146gp91 promoter in
BM cells expressing the myeloid marker Mac11 was signif-
icantly higher than the expression levels detected in
vector-transduced Lin–SCA11Kit1 (LSK) HSPC (Fig.
1C). No GFP expression was detected in either total cul-
tured lineage-negative (Lin–) cells or LSK cells following
transduction with lentiviral vectors carrying the IHK pro-
moter. Furthermore, a remarkable increase in GFP and
GALC expression from the IHK promoter was observed
following HMBA-mediated differentiation of MEL cells
(Fig. 1B). On the other hand, efficient GFP expression
from lentiviral vectors carrying the CMV promoter was
detected in total cultured Lin– and LSK cells. In addition,
CMV containing vectors exhibited significantly higher lev-
els of transgene expression in 293T and LSK cells com-
pared with the expression levels detected in THP-1 and
MAC11 cells, respectively. Premised on the cell specificity
of transgene expression exhibited by these vectors in vitro,
we sought to employ lentiviral vectors carrying the cell-
specific promoters as a means to deliver GALC expression
cassettes to donor HSPCs. As described below and in Fig-
ure 3B and Table III, vector-transduced HSPC efficiently
engrafted the host BM following conditioning. Thus, BM
chimerism of donor cells containing one or more vector
genomes expressing the GALC under these cell-specific
promoters was not lower than the chimerism of nontrans-
duced HSPC. These findings indicate that efficient lentivi-
ral vector-mediated delivery of GALC expression cassettes
comprising cell specific promoters can be achieved without
posing biosafety concerns associated with altering the host
miRNA system.
TABLE I. Primary Antibodies Used
Antigen Description of Immunogen
Source, host species, catalog No.,
clone or lot No., RRID Concentration used
Insulin-like growth factor 2
Receptor (IGF2R/
CI-M6PR/CD222)
Synthetic peptide corresponding to residues





























SCFR; stem cell factor
receptor CD117 (cKit)






mouse T-cell receptor (CD3e), mouse
splenic cells (target CD11b); mouse
abelson leukemia virus-induced pre-B
tumor cells (target B222); mouse fetal
liver (target Ter119, erythroids marker);
Ly6G/6C
BD Biosciences, hamster antibody
cocktail, 561301,
RRID:AB_10611731
20 ml/100 ml/106 cell
(flow cytometry)
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Fig. 1. Novel lentiviral vectors support erythroid- and myeloid-
specific transgene expression. A: Novel self-inactivating (SIN) vectors
carrying erythroid (IHK)- and myeloid (146gp91)-specific promoters.
ssp, Synthetic secretory signal peptide; psp, parental secretory signal
peptide; co-GALC, codon optimized mouse GALC cDNA; myc,
myc tag; 146gp91, myeloid-specific promoter; IHK, erythroid/mega-
karyocyte-specific promoter; IRES, internal ribosome entry site; WP,
woodchuck hepatitis virus posttranscriptional regulatory element; DU3
LTR, Self-inactivating (SIN) LTR deleted of the parental enhancer
promoter. B: Lentiviral vectors carrying the IHK promoter support
erythroid-specific transgene expression in vitro. FACscan analysis of
GFP expression in mouse erythroleukemia (MEL) cells, human 293T
cells, mouse Lin– cells, and mouse Lin–Sca11Kit1 (LSK) cells follow-
ing transduction with lentiviral vectors carrying either the IHK pro-
moter (pTK1580 and pTK1582) or the CMV promoter (pTK945).
MEL and 293T cells were analyzed either before or after HMBA-
induced erythroid differentiation. Untransduced MEL and 293T cells
served as controls. Percentage of GFP-positive cells is shown. Mean
fluorescence intensity (MFI) presents levels of GFP expression. Note
that GFP expression from IHK-containing lentiviral vectors was
detected only in HMBA-induced MEL cells. C,D: Lentiviral vectors
carrying the 146gp91 promoter support myeloid-specific transgene
expression in vitro. C: Lentiviral vectors carrying the GFP reporter
gene under control of either the myeloid 146gp91 promoter
(pTK1607) or the CMV promoter (pTK945) were employed to trans-
duce human 293T cells, cells of the human THP-1 monocyte cell
line, the above-mentioned mouse LSK cells, and mouse BM cells
expressing the macrophage surface marker Mac11. FACScan analysis
of GFP expression was employed as described for B. Note that high
levels GFP expression from the CMV promoter were detected in all
target cells excluding the Thp1 cells. CMV-regulated expression was
higher in LSK than in Mac11 cells. On the other hand, GFP expres-
sion driven by146gp91 was high in THP1 and very low in 293T cells.
Furthermore GFP expression level in Mac11 cells was significantly
higher than the level of expression detected in LSK cells. D: Lentiviral
vectors carrying the firefly luciferase under control of either a myeloid
promoter (pTK1607) or a CMV promoter (pTK993) transduced
293T and THP-1 cells. Luciferase activity in relative light unit (RLU)
was normalized per milligram protein and VCN per cell. Luciferase
activity generated by each vector in 293T served as a reference base-
line. The ratio or fold expression of luciferase activity from these vec-
tors in THP1 cells relative to luciferase expression in 293T cells was
calculated. Note that CMV expression in THP-1 cell was dramatically
lower than its expression in 293T cells. On the other hand, luciferase
expression per vector genome from the myeloid promoter increased
33-fold relative to its expression in 293T cells.
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L-Cycloserine Enhances IGF2R Expression in Twi
Mouse CNS
The cornerstone of cell- and gene therapy-based
therapeutic protocols for LSDs is the phenomenon of
“cross-correction,” in which donor cell-secreted, M6P-
comprising enzymes are taken up by host enzyme-deficient
cells (either in the periphery or in the CNS). Sufficient
expression of IGF2R, the CI-M6PR in treated cells, is
essential to facilitate this therapeutic pathway. However,
supraphysiological levels of functional GALC following
viral vector-mediated gene delivery (either alone or in
combination with BMT) to twi mouse CNS and PNS
resulted in only moderate prolongation of average mouse
life span (Lin et al., 2007). Similarly, a substrate reduction
approach using L-cycloserine, an inhibitor of sphingolipids
synthesis (which should also decrease accumulation of toxic
undegraded metabolites such as psychosine), failed to pro-
long twi mouse life span (Hawkins-Salsbury et al., 2015).
However, by combining L-cycloserine treatment with
BMT and AAV vector-based GALC delivery, Hawkins-
Salsbury et al. dramatically prolonged the life span of
treated twi mice. Premised on these studies, we theorized
that an L-cycloserine-mediated increase in IGF2R expres-
sion facilitated uptake of functional GALC secreted from
donor HSPC and from AAV vector-transduced cells by
twi cell populations that naturally express insufficient levels
of the M6P receptor. To test this hypothesis, we employed
a semiquantitative immunohistochemistry analysis to char-
acterize IGF2R levels in either L-cycloserine treated or
na€ıve twi mice. As shown in Figure 2A,B, L-cycloserine
treated-mice exhibited significantly higher levels of cellular
IGF2R(Student’s t test, n 5 3, P 5 0.006). These data fur-
ther support the notion that insufficient IGF2R expression
limits the efficacy of BMT and gene therapy-based thera-
peutic protocols to cure KD.
Efficient M6P-Independent Uptake of a Novel
GALC-ApoE1 Receptor Binding Domain (GALC-
AErbd) Fusion Protein
Intrigued by the notion that low levels of IGF2R in
various CNS and PNS cell populations potentially limit
the efficacy of HSPC transplantation and gene therapy
protocols for treating KD, we sought to facilitate cellular
uptake of secreted GALC independently of the M6P
pathway. To this end, we developed a novel fusion pro-
tein comprising the GALC and the AErbd.
This approach was premised on earlier studies in
which fusion of the AErbd to the lysosomal protein a-L-
iduronidase (IDUA) facilitated uptake of the novel pro-
tein by blood–brain barrier (BBB) endothelial cells, trans-
cytosis to the CNS, and delivery to astrocytes and
neurons throughout the cerebral cortex via the LRP-1
pathway (independently of the M6P pathway) (Wang
et al., 2013; Dai et al., 2014; El-Amouri et al., 2014). The
novel GALC-AErbd cDNA was cloned into lentiviral
vectors under control of a CMV, an IHK, or a 146gp91
promoter (Fig. 2C). To characterize the efficiency of
LRP-1-mediated GALC uptake, 293T cells were trans-
duced with lentiviral vectors expressing either GALC or
GALC-AErbd cDNAs. Conditioned media were collect-
ed from vector-transduced cells and applied to 293T cells
and human fibroblasts derived from KD patients, in either
the absence or the presence of M6P. Cellular activity of
GALC (Wiederschain et al., 1992) in conditioned media-
treated cells served as a surrogate marker for cellular
uptake of GALC and GALC-AErbd. Activity of GALC
in untreated healthy and KD human fibroblasts served as
reference controls. As shown in Figure 2D,E the presence
of M6P, a competitive inhibitor of the IGF2R-mediated
protein uptake pathway, efficiently inhibited uptake of
conditioned media GALC by both 293T cells and human
KD fibroblasts. On the other hand, M6P treatment had a
minimal yet measurable effect on cellular uptake of
GALC-AErbd. These data indicate that cellular uptake of
the novel GALC-AErbd fusion protein can be mediated
independently by the IGF2R- and the LRP-1-specific
pathways. This attribute of GALC-AErbd broadens the
spectrum of target cells that can benefit from the “cross-
correction” phenomenon in current and future therapeu-
tic regimens for KD (Polavarapu et al., 2007; Lillis et al.,
2008).
Twi mouse life span following HSPCT correlates
with the aggressiveness of the preconditioning
protocol.
Earlier studies suggested that both host conditioning
with either irradiation or chemotherapy and damage to
the CNS are required for efficient donor HSPC engraft-
ment in rodent brains (Priller et al., 2001; Mildner et al.,
2007; Davoust et al., 2008).
Note that Bu was the major chemotherapy agent
employed in earlier lentiviral/HPCT-based human clini-
cal trials of neurodegenerative diseases (Cartier et al.,
2009; Aiuti et al., 2013) as well as in allogeneic HPCT
for KD (Escolar et al., 2005), yet irradiation-conditioning
protocols have been employed in most HSPCT-based
preclinical trials investigating KD (Lin et al., 2007; Gent-
ner et al., 2010; Hawkins-Salsbury et al., 2015). This lim-
its our ability to accurately interpret the therapeutic
outcomes described in the above-mentioned preclinical
studies. Furthermore, the correlation between the levels
TABLE II. Novel Lentiviral Vectors Carrying the IHK Promoter
Demonstrate Erythroid Specific Expression of GALC in Differen-
tiated MEL Cells*
Galc activity (nmol/hr/mg protein)
Cont pTK1580 pTK1582
Na€ıve MEL ND 6.46 8.47
Differentiated MEL (HMBA) ND 30.70 34.03
*MEL cells were transduced with lentiviral vectors carrying codon-
optimized murine GALC cDNA under control of the erythroid/mega-
karyocyte-specific promoter IHK (pTK1580, pTK1582). Vector-
transduced MEL were induced to undergo erythroid differentiated by
5 mM HMBA. GALC activity in vector-transduced MEL cells prior to
and after differentiation was determined and served as a surrogate marker
for IHK promoter activity. Note the robust increase in IHK activity fol-
lowing HMBA-induced differentiation.
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of donor/host chimerism in the bone marrow and the
therapeutic benefits of HPCT in KD has not been estab-
lished. Thus, it is imperative that we further characterize
the effects of the conditioning protocol and host health
status on the therapeutic outcome of HSPCT in the twi
mouse model of KD. To this end, as shown in Figure 4A
and Table III, healthy donor total BM cells (BoyJ express-
ing CD45.1) were transplanted into host mice (C57B6
expressing CD45.2) including either twi (GALC–/–;
groups A, B, D, and E) or healthy hosts (groups C and F).
Note that the healthy host population comprised hetero-
zygous twi (GALC1/–) and wild type mice (GALC1/1).
Specifically, at postnatal day 8, host mice were condi-
tioned by i.p. injection of either 12.5 (groups A–C) or
25 mg/kg Bu (groups D–H) and 1 day later were given
na€ıve donor total bone marrow cells (5–6 3 107 cells/
mouse, groups A–F) i.p. Mouse body weight was mea-
sured every 2–3 days. To facilitate characterization of
Fig. 2.
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donor cells engraftment in twi host CNS, mice were sac-
rificed at postnatal days 77–90 (groups A and D). All oth-
er twi mice died naturally or were euthanized in
accordance with UNC Institutional Animal Care and Use
Committee (IACUC) protocol. As shown in Figure
3A,B, untreated twi mice maintained close to normal
body weight until week 5, after which dramatic weight
loss followed by death occurred in all mice before postna-
tal day 46. Healthy BMT-treated mice, which were con-
ditioned with Bu 12.5 mg/kg demonstrated a body
weight increase curve that was not significantly different
from the curve of untreated healthy mice. However, con-
ditioning of healthy mice with 25 mg/kg Bu inhibited
gain in mouse body weight for approximately 2 weeks,
after which a continuous increase in body weight was
observed. However, at postnatal day 180, the average
body weight of this group of mice was still significantly
lower than the body weight of untreated or 12.5 mg/kg
Bu-treated mice. For the first 7 weeks of life, the body
weight curve of twi mice treated with 25 mg/kg Bu was
not significantly different from the body weight curve of
their healthy counterparts, which received the same treat-
ment. Interestingly, this group of mice failed to gain
weight after postnatal week 7. The maximal average body
weight of these mice was 12.5 g; however, in contrast to
untreated twi mice, death in this group was not preceded
by body weight loss. Because of the milder conditioning
protocol, twi mice treated with 12.5 mg/kg of Bu dem-
onstrated early gains in body weight, which started to
decline at postnatal week 5 and stabilized within 1 week.
The average body weight at death of this group of mice
was not significantly different from the average body
weight of their twi counterparts that were conditioned
with 25 mg/kg of Bu. On the other hand, a highly signifi-
cant difference was observed in the effects of the two
conditioning protocols on the life span of HSPCT-treated
twi mice. As shown in Figure 3C, the average life span of
twi mice conditioned with 25 mg/kg Bu was significantly
longer than the average life span of those conditioned
with 12.5 mg/kg Bu (Student’s t-test, n 5 4 and 9,
P 5 0.014).
The average life span of twi mice following HSPCT
did not correlate with the level of donor/host chi-
merism in the BM.
Next we sought to investigate whether the longer
life span of twi mice following high-dosage of Bu
(25 mg/kg) conditioning protocol was secondary to a
more efficient engraftment of donor HSPC in the host
BM compartment. To this end mouse pluripotent hema-
topoietic Lin–Sca11Kit1 (LSK) cells isolated from bone
marrow of all mouse groups A–H were FACscan analyzed
for CD45.1 (donor)- and CD45.2 (host)-expressing cells.
As shown in Figure 4A,C and Table III, with the excep-
tion of a single mouse (group C mouse K67L1) all mice
in all treatment groups exhibited high levels of chimerism
(>90%). These data strongly suggest that the levels of BM
chimerism cannot explain the difference in average twi
mouse life span following conditioning with high and
low Bu doses. No difference in chimerism was observed
between wild-type and twi mouse hosts.
The levels of donor/host cell chimerism in twi
mouse hosts CNS were significantly higher than
those found in wild-type hosts’ CNS.
To understand better the mechanism by which the
conditioning protocol affects the life span of BMT-treated
twi mice, we characterized donor/host chimerism in the
Fig. 2. Induction of IGF2R expression in mouse CNS by L-cycloserine
and efficient uptake of a novel GALC-AErbd fusion protein via an
M6P-independent pathway. A,B: Analysis of IFG2R expression in L-
cycloserine (L-cys)-treated and untreated twi mouse CNS. A: Represen-
tative sections from untreated (I–III) and L-cys-treated (IV–VI) twi
mouse diencephalon. Hematoxylin and eosin (HE) staining (I, IV) shows
no significant morphological differences between L-cys-treated and
untreated mice. Immunohistochemical (IHC) staining (II, V) shows
enhanced expression of IGF2R in L-cys treated mouse diencephalon.
To semiquantify expression of IGF2R in treated and untreated twi
brain, the IHC-stained sections were masked by red (3 1 positive),
orange (2 1 positive), yellow (1 1 positive), and blue (no signal; III, VI).
All panels are X20. Scale bar = 100 mm. B: Semiquantification of
IGF2R expression using IHC-stained sagittal brain sections of L-cys
treated and untreated twi mice. Red and orange signals were quantified
as positive cells. The percentage of positive cells between two groups
were compared by two-tailed Student’s t-test, N 5 3 in each group,
P 5 0.006. C: Depiction of the lentiviral vectors used to characterize
uptake of the novel GALC-AErdb and its usage. ssp, Synthetic secretory
signal peptide; psp, parental secretory signal peptide; co-GALC, codon
optimized mouse GALC cDNA; myc, myc tag; AErbd, ApoE receptor
binding domain; 146gp91, myeloid-specific promoter; IHK, erythroid/
megakaryocyte-specific promoter; WP, woodchuck hepatitis virus post-
transcriptional regulatory element; DU3 LTR, SIN LTR deleted of the
parental enhancer promoter. D: Uptake of GALC and GALC-AErbd
by 293T cells via the IGF2R and the LRP-1 pathways. 293T cells were
cultured either in the presence or in the absence of 1mM M6P (a com-
petitive inhibitor of protein uptake via the IGF2R pathway) in condi-
tioned media containing either GALC (generated by pTK1557-
transduced cells) or GALC-AErbd (generated by pTK1664-transduced
cells). The GALC activity in these 293Tcells served as a surrogate mark-
er for GALC uptake. Cellular GALC activity in the absence of M6P
served as a reference value, considered to be 100%. The ratio of cellular
GALC activity in the presence of M6P relative to GALC activity of the
same protein without M6P was calculated. Uptake of GALC
(pTK1557) was efficiently inhibited by the presence of 1 mM M6P,
whereas uptake of the GALC-AErbd fusion protein (pTK1664) was
only slightly affected. E: Uptake of GALC and GALC-AErbd by
healthy and KD human fibroblasts cells via the IGF2R and the LRP-1
pathways. Human fibroblasts isolated from healthy donors (Cont) and
KD patients (Krabbe) were cultured either in the presence or absence of
M6P (a competitive inhibitor of protein uptake via the IGF2R pathway)
in conditioned media containing either GALC (generated by pTK1578-
transduced cells) or the GALC-AErbd (generated by pTK1665-
transduced cells). The levels of GALC activity in na€ıve KD and healthy
human fibroblasts are shown. Note that the presence of 2.5 mM M6P
efficiently inhibited GALC uptake, whereas GALC-AErbd uptake was
not significantly affected in the presence of M6P.
BMT-Lentiviral Vectors Therapy for Krabbe’s Disease 1161
Journal of Neuroscience Research
CNS of treated mouse groups A, C, D, and F. To this
end, either CNS enriched microglia and leukcocytes or
CD11b-gated cells were analyzed by FACscan for
CD45.1(donor) or CD45.2 (host) expression. As shown
in Figure 4B,C and Table III, no significant differences in
the levels of donor/host chimerism in the CNS were
found between low (12.5 mg/kg, group A)- and high
(25 mg/kg, group D)-dose Bu-treated twi mice. On the
other hand, the level of chimerism in twi mouse CNS
was always significantly higher than the chimerism level
in the CNS of their healthy counterparts (Stuendent’s t
test, n 5 4, P 5 0.002 for CNS enriched microglia and
leukocytes and P 5 1.6 3 10-7 for CD11b-gated cells in
low-dose groups; P 5 0.002 for CNS enriched microglia
and leukocytes and P 5 7.3 x 10-7 for CD11b-gated cells
in high-dose groups). These data suggest that KD-
induced pathology may enhance the efficiency of engraft-
ment and colonization of hematopoietic-derived donor
cells in the host CNS.
Transduction of HSPC with lentiviral vectors carry-
ing the GALC-AErbd cDNA, under the control of
either a myeloid- or an erythroid/megakaryocyte-
specific promoter, does not reduce engraftment
efficiency in host BM.
To increase the efficacy of BMT for KD, we sought
to overexpress the novel GALC-AErbd protein in
HSPC-derived cells. We expected that high levels of
donor cell-secreted GALC-AErbd, whose uptake by
Fig. 3. Effects of Bu-based conditioning protocols on clinical parame-
ters following HSPCT in the twi mouse model of KD. A: Weight
gain curves of healthy littermates (control) and twi mice following
conditioning protocols that were premised on i.p. injection of either
12.5 mg/kg or 25 mg/kg Bu at postnatal day 8. At postnatal day 9, all
conditioned mice were given 5–6 3 107 total BM cells. Mouse weight
was measured every 2–3 days. Untreated healthy and twi mice served
as controls. B: Weight gain curves of healthy littermates (control) and
twi mice following a conditioning protocol in which 25 mg/kg Bu
was administered by i.p injection at postnatal day 8. At postnatal day
9, one group of either conditioned healthy mice (controls) or condi-
tioned twi mice was given via i.p. injection 1 3 106 pTK1667-
transduced Lin– cells, 1 3 106 pTK1784-transduced Lin– cells, and
1 3 107 total bone marrow cells. In addition, one group of either con-
ditioned healthy mice or conditioned twi mice received 5–6 3 107
total BM cells. A group of untreated twi mice served as a control.
Mouse weight was measured every 2–3 days. C: Life span of three
groups of twi mice (groups I–III) following different conditioning and
HSPCT protocols. Mice in group I were conditioned with a low
dose (12.5 mg/kg) of Bu and received 5–6 3 107 total BM cells. Mice
in group II were conditioned with a high dose (25 mg/kg) of Bu and
received 5–6 3 107 total BM cells. Mice in group III were condi-
tioned with a high dose (25 mg/kg) of Bu and received 1 3 106
pTK1667-transduced Lin– cells, 1 3 106 pTK1784-transduced Lin–
cells, and 1 3 107 total BM cells. Student’s t-test demonstrated a sig-
nificant increase (n 5 4 and 9, P 5 0.014) in mouse life span following
conditioning with high-dose Bu compared with the life span of mice
conditioned with low-dose (12.5 mg/kg) Bu. Asterisk indicates that
the mice were sacrificed for data collection.
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GALC-deficient host cells is mediated by two indepen-
dent pathways (M6P and LRP-1 pathways), would fur-
ther extend the life span of BMT-treated twi mice. To
this end, Lin– cells isolated from donor BoyJ (CD45.1)
mice were transduced at an m.o.i. of 50 with lentiviral
vectors from which the GALC-AErbd cDNA is expressed
Fig. 4.
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under control of either the myeloid-specific promoter
146gp91 (pTK1667) or the erythroid/megakaryocyte-
specific promoter IHK (pTK1784). At postnatal day 8,
twi and wild-type control mice were conditioned by i.p.
injection of Bu (25 mg/kg). At postnatal day 9 mice were
injected i.p. with the these vector-transduced cells
(1 3 106 cells/mouse of pTK1667-transduced Lin– cells
and 1 3 106 cells/mouse of pTK1784 vector-transduced
Lin– cells) along with 107 na€ıve total BM cells (Table III,
groups G and H). Wild-type and twi mice receiving na€ıve
total BM cells (5–6 3 107 cells/mouse) served as controls.
Mouse weight was determined every 2–3 days. Mice
were euthanized according to UNC IACUC protocol.
VCN in mouse total BM cells was determined by qPCR.
In addition donor/host chimerism in isolated LSK cells
and in treated mouse CNS were determined by FACScan
analysis as described above. As shown in Figure 3C,
HSPC transduced with lentiviral vectors carrying the
GALC-Arbd did not extend the life span of BMT-treated
twi mice beyond the average life span of these mice fol-
lowing BMT with nontransduced donor HSPC. Similar-
ly, the weight gain curve of either twi or wild-type mice
treated with vector-transduced HSPC was not significant-
ly different from the weight gain curve of their counter-
parts, which received donor nontransduced total BM cells
(Fig. 3B). These data indicated that, under the conditions
described above, lentiviral vector delivery of GALC-
AErbd to donor HSPC did not increase the therapeutic
benefits of BMT to twi mice. To evaluate the efficiency
of lentiviral vector transduction and engraftment of
vector-transduced HSPC, we characterized donor/host
chimerism and VCN in the BM of wild-type and twi
mice. As shown in Table III, the efficiency of engraftment
and colonization of HSPC transduced with lentiviral vec-
tors from which the GALC-AErbd is expressed under the
control of erythroid- and myeloid-specific promoters is
similar to that of BM engraftment of nontransduced
HSPC. VCN in BM of twi mice (ranging between 0.46
and 1.24) was higher than the VCN in BM of wild-type
mice (ranging between 0.02 and 0.82). Altogether these
data indicated that HSPC transduced with lentiviral vec-
tors carrying GALC under control of cell-specific pro-
moters could colonize the BM compartment in wild-type
and twi mice. Note that in earlier studies significantly
higher VCN (five to eight copies) in host mouse BM was
required to moderately prolong the life span of GALC
deficient mice (Gentner et al., 2010; Ungari et al., 2015).
Clearly, additional studies using higher m.o.i. to achieve
higher VCN in host BM are required to accurately evalu-
ate the therapeutic potential of the GALC-AErbd fusion
protein.
DISCUSSION
Allogeneic HSPCT with HLA-matched healthy donor
HSPC has been the standard therapeutic approach for a
plethora of rare metabolic genetic disorders (such as
LSDs, including KD). Since the early 1980s more than
2,000 HSPCTs were performed to treat genetic disorders
(Boelens et al., 2014). The degree of success of this
approach is mainly disease specific. With regard to LSDs,
the spectrum of endpoint therapeutic benefits ranges
between largely inefficient even in animal models (Hel-
dermon et al., 2013) to highly beneficial in human
patients (Boelens et al., 2013). However, even in the
Fig. 4. Engraftment efficiency in control and twi mouse BM and
CNS following BMT with Bu-based conditioning protocols. A:
Engraftment efficiency of BoyJ donor cells (expressing the CD45.1
marker) in healthy and twi mouse BM following BMT and condi-
tioning protocols, using either 12.5 or 25 mg/kg Bu. Percentage of
donor cells in LSK cell populations isolated from these treated mice
was determined by FACscan analysis with antibody staining directed
to the donor-specific CD45.1 marker. Note that no significant differ-
ences were observed among the different treatment groups. LSK cells
isolated from either untreated BoyJ donor (CD45.1) and untreated
healthy host (CD45.2) mice served as positive and negative controls.
B: Engraftment efficiency of BoyJ donor cells (expressing the CD45.1
marker) in healthy and twi mouse CNS following BMT and condi-
tioning protocols with either 12.5 or 25 mg/kg Bu. Percentage of
donor cells in either microglia- or leukocyte-enriched cell populations
or CD11b1 cells from treated mouse CNS was determined by FACs-
can analysis with antibody staining directed to the donor-specific
CD45.1 marker. Note that significant differences in engraftment of
donor cells (CD45.1) in treated mouse CNS were observed among
the different treatment groups (in contrast to the lack of differences in
engraftment efficiency of donor cells in host BM). CNS cells isolated
from either untreated BoyJ donors (CD45.1) or untreated healthy host
(CD45.2) mice served as positive and negative controls. Student’s tests
were performed between indicated groups, n 5 4 for all groups, P val-
ues are listed in the figure. C: FACscan analysis of donor/host chime-
rism in host BM and CNS following low- and high-dose Bu
conditioning and HSPCT in either healthy control (ctl) or twi mice.
All host mice (healthy control and twi) expressed the CD45.2 marker.
All donor cells derived from BoyJ mice expressd the CD45.1 marker.
Top row shows FACscan analysis of CD45.1 (donor) and CD45.2
(host) protein expression in Lin–Sca11Kit1 (LSK) cells isolated from
either healthy (ctl) or twi host mice following conditioning with
either low-dose (12.5 mg/kg) or high-dose (25 mg/kg) Bu. Untreated
BoyJ CD45.1 and the host control (CD45.2) served as references to
CD45.1 and CD45.2 expressing cells, respectively. Note highly effi-
cient engraftment in healthy and twi hosts receiving either low- or
high-dose Bu-based conditioning. Middle row shows FACscan analy-
sis of CD45.1 (donor) and CD45.2 (host) protein expression in CNS
enriched with microglia and leukocytes isolated from either healthy
(ctl) or twi host mice following conditioning with either low-dose
(12.5 mg/kg) or high-dose (25 mg/kg) Bu. Untreated BoyJ CD45.1
and the host control (CD45.2) served as references to CD45.1 and
CD45.2 expressing cells, respectively. Note that a higher level of chi-
merism was obtained in twi host mice. High-dose Bu-based condi-
tioning appears to increase chimerism in twi mouse. Bottom row
shows FACscan analysis of CD45.1 (donor) and CD45.2 (host) pro-
tein expression in CD11b1 expressing cells isolated from either
healthy (ctl) or twi host mice following conditioning with either low-
dose (12.5 mg/kg) or high-dose (25 mg/kg) Bu. Untreated BoyJ
CD45.1 and the host control (CD45.2) served as references to
CD11b1 gated cells expressing only CD45.1 and CD45.2,
respectively.
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most successful scenario—HSPCT applied to MPS-IH
(Hurler disease) patients—a complete cure is far from
being achieved (Aldenhoven et al., 2015). Treating pre-
symptomatic KD patients with HSPCT preserves most of
their cognitive function. However, progressive deteriora-
tion of the patients’ PNS severely affects gross motor
function and expressive language (Escolar et al., 2005;
Duffner et al., 2009). We assert that the limited efficacy
of the current HSPCT protocols fior curing KD is linked
to the basic biological processes on which the HSPCT
therapeutic approach for KD is premised. These include
the ability of donor HSPC to efficiently colonize the host
in proximity to cell populations that are vulnerable to
GALC deficiency. Furthermore, the therapeutic effects of
HSPCT are heavily dependent on the “cross-correction”
phenomenon, so it is imperative that these host target
populations express sufficient levels of IGF2R to facilitate
efficient uptake of donor-derived GALC. Overall, this
study was premised on the notion that two independent
mechanisms potentially limit the efficacy of current
HSPCT protocols at curing KD. Specifically, we hypoth-
esized that both inefficient conditioning protocols (which
limit the number and biodistribution of donor-derived
microglia in host CNS) and inefficient host cell uptake of
donor cell-secreted GALC (resulting from lack of suffi-
cient IGF2R) should be addressed to maximize the thera-
peutic benefits of HSPCT protocols for KD patients.
In addition, we have characterized some of the
obstacles and potential solutions associated with the strate-
gy of combining lentiviral vector delivery of GALC with
HSPCT-based therapy for KD. The ability of lentiviral
vectors to deliver and maintain long-term transgene
expression in HSPC and their progenies opens new direc-
tions in HSPCT-based therapy for genetic disorders in
general and for KD in particular (Miyoshi et al., 1999;
Cartier et al., 2009; Aiuti et al., 2013; Biffi et al., 2013).
Specifically, lentiviral vectors carrying functional GALC
to autologous HSPC circumvent the need to identify an
HLA-matched donor. In addition, overexpression of
GALC in vector-transduced cells should in theory broad-
en the spectrum of target cells that can benefit from the
phenomenon of cross-correction. However, in recent
preclinical studies using mouse models of KD, lentiviral
vector-mediated GALC delivery to HSPC revealed
potential limitations in this approach. Overall only a very
mild effect on GALC-deficient mice life span could be
achieved, and only in mice showing very high VCN in
engrafted donor cells (Gentner et al., 2010; Ungari et al.,
2015). Furthermore, GALC cytotoxicity, which inhibited
engraftment of vector-transduced HSPC, necessitated
incorporation of an HSPC-specific miRNA target
sequence to minimize GALC expression in and to facili-
tate efficient engraftment of vector-transduced HSPC.
Notably, a heterogeneous cell population with an average
VCN of 8 usually contains cells with VCN higher than
25. The combination of very high VCN and vector
design comprising the target sequence to host miRNA
raises biosafety concerns. These include the possibility of
inadvertently altering the host miRNA system via the
“sponge effect” described earlier in which high levels of
exogenous miRNA target sequence served as a competi-
tive inhibitor decoy that suppressed specific miRNA
function (Ebert and Sharp, 2010). We assert that weak-
nesses in the lentiviral vector system should be addressed
by further vector development rather than by manipulat-
ing host biological pathways. To this end, we developed
novel lentiviral vectors from which the reporter genes
GFP and firefly luciferase (as well as the GALC and the
GALC-AErbd fusion protein) were expressed under con-
trol of either an erythroid/megakaryocyte (IHK)- or a
myeloid (146gp91)-specific promoter (Moreau-Gaudry
et al., 2001; He et al., 2006; Barde et al., 2011). The nov-
el vectors demonstrated cell-specific expression in vitro
and facilitated efficient GALC-AErbd delivery to and
engraftment of vector-transduced HSPC. Donor/host
chimerism in host BM following transplantation with
vector-transduced cells was equivalent to the chimerism
achieved following engraftment of untransduced HSPC.
VCN of the novel vectors in twi mouse BM ranged from
0.46 to 1.24. Because, in addition to the vector-
transduced Lin– cells, the transplanted donor cell popula-
tion included 107 total BM cells, we speculate that VCN
in engrafted transduced cells was higher than that
described above.
The mild effect of high lentiviral VCN on the aver-
age life span of HSPCT-treated GALC-deficient mice
(Gentner et al., 2010; Ungari et al., 2015) suggested that
high levels of vector/donor cell-derived functional
GALC would not cure KD patients. This phenomenon
was in line with similar studies in which supraphysiologi-
cal levels of AAV vector-delivered GALC failed to signifi-
cantly alter the life span of twi mice (Lin et al., 2007). We
theorized that lack or insufficient levels of IGF2R in
GALC-deficient host cells rendered the cross-correction
phenomenon inefficient. This notion is supported by sev-
eral studies showing that expression of IGF2R is develop-
mental age and gender dependent (Nissley et al., 1993;
Gonzalez-Parra et al., 2001; Hawkes and Kar, 2003,
2004; Romano et al., 2005; Jofre et al., 2009). Further-
more, analysis of IGF2R expression in healthy and Alz-
heimer’s disease human brains demonstrated regional and
cell type specificity (Kar et al., 2006). GALC was shown
to express primarily in neurons and not on other cell types
in the CNS (astrocytes, oligodendrocytes) that can benefit
from the cross-correction phenomenon. The fact that
IGF2R is biallelically expressed in human tissues (Kal-
scheuer et al., 1993) and is genomically imprinted in mice
(Barlow et al., 1991) limits the ability to interpret some of
the results obtained in mouse models. Here we demon-
strated for the first time an L-cycloserine-mediated
increase of IGF2R. These findings support our notion
that the dramatic prolongation in twi mouse life span
upon combining L-cycloserine treatment with HSPCT
and AAV vector-mediated GALC delivery is secondary to
an L-cycloserine-induced increase in IGF2R (Hawkins-
Salsbury et al., 2015). Additional characterization of this
phenomenon with identification of novel small molecules
that enhance IGF2R expression may improve current
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therapeutic protocols for KD. Intrigued by these findings,
we sought to circumvent the need to increase IGF2R
expression by directing GALC uptake via an IGF2R-
independent pathway. To this end, we developed the
GALC-AErbd fusion protein, whose uptake by GALC-
deficient cells is mediated by two independent pathways,
namely, the IGF2R and the LRP-1 pathways. Our
approach was premised on an earlier study demonstrating
efficient LRP-1-mediated uptake of erythrocyte/mega-
karyocyte-secreted IDUA-AErbd by neurons and astro-
cytes throughout the cerebral cortex (Wang et al., 2013).
Indeed, here we demonstrate the ability of 293T and
human GALC-deficient fibroblasts to take up the GALC-
AErbd independently of the IGF2R pathway efficiently.
We expected that the novel GALC-AErbd would broad-
en the spectrum of host cells that benefit from the phe-
nomenon of cross-correction. The fact that the life span
of twi mice engrafted with HSPC transduced with
GALC-AErbd-expressing vectors was not significantly
different from the life span of their counterparts, which
received nontransduced total BM cells, was not highly
surprising, especially because VCN in these treated mice
BM was not higher than 1.24. Note that, in earlier stud-
ies, in which lentiviral vectors were employed to deliver
GALC to HSPC, relatively high VCN (6–10) in host BM
was required to achieve merely mild prolongation in the
life span of GALC-deficient mice (Gentner et al., 2010;
Ungari et al., 2015). Facilitating cellular uptake of donor-
cell secreted GALC-AErbd via an M6PR-independent
pathway and inducing overexpression of IGF2R by L-
cycloserine are two independent strategies to allow effi-
cient HPCT-mediated cross-correction of GALC defi-
ciency in twi mouse CNS cells expressing low levels of
IGF2R. The GALC-AErbd approach does not require
significant modifications to current HPCT-based proto-
cols and if successful provides major long-term therapeu-
tic benefits to HPCT-treated patients. However, the
efficacy of this approach, which is dependent on the level
of LRP-1 in KD patients’ CNS, has not been established.
Furthermore, employing this approach to treat other
LSDs requires the development of different AErbd-fusion
proteins. The ability of an L-cycloserine/gene therapy
combination to treat twi mice efficiently has opened a
new direction in KD therapy. However, the broad spec-
trum of L-cycloserine activity and its inherent cytotoxici-
ty render this small molecule unsuitable for human
clinical trials. Clearly, less toxic small molecules that upre-
gulate IGF2R expression in vivo have to be identified,
and their ability to synergize with gene and cell therapy
protocols in curing KD has to be established. Further-
more, this approach necessitates life-long treatment.
Thus, we assert that additional studies are needed to char-
acterize the therapeutic mechanism of this approach and
to establish its efficacy (either separately or in combina-
tion) for treating LSDs prior to considering their usage in
clinical applications.
However, we also realize that a suboptimal condi-
tioning protocol might negatively affect the efficacy of
HSPCT for correcting GALC deficiency in preclinical
models. Because Bu is the major chemotherapy agent
employed in human clinical trials of neurodegenerative
diseases (Cartier et al., 2009; Aiuti et al., 2013) as well as
in allogeneic HPCT for KD (Escolar et al., 2005), we
sought to characterize the dose effects of Bu on the effica-
cy of HSPCT in the twi mouse model. Overall, the aver-
age life span of HSPCT treated twi mice in this study was
considerably longer than the average life span of twi mice
conditioned by irradiation (Lin et al., 2005, 2007; Gent-
ner et al., 2010; Ungari et al., 2015). This limits our abili-
ty to evaluate the efficacy of different therapeutic
measures that were tested in irradiated twi mice. The
results of this study clearly demonstrate direct correlation
between the dose of Bu and the capacity of HSPCT pro-
tocols to prolong the average life span of twi mice. Fur-
thermore, colonization of donor cells in twi mouse CNS
was significantly more efficient than the engraftment of
the same donor cells in healthy mouse CNS. These find-
ing are in line with several earlier studies concluding that
both effective conditioning protocols and host CNS
pathology are required for optimal colonization of the
host CNS with donor hematopoietic progenies (Priller
et al., 2001; Mildner et al., 2007; Davoust et al., 2008).
This notion raises the possibility that various regions in
twi mouse CNS that are relatively healthy at the time of
HSPCT are not efficiently colonized with donor cells.
Clearly, further optimization of the conditioning/
HSPCT protocols is needed to maximize the clinical out-
come of HSPCT in the twi model of KD. We anticipate
that the results of this study will pave the way for the
development of new GALC fusion proteins with a broad-
ened spectrum of target cells in the CNS.
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